Background/Objective: Elevated pulse wave velocity (PWV) and central aortic blood pressures are independent predictors of increased cardiovascular morbidity and mortality in hemodialysis (HD) patients. Oxalic acid is a uremic retention molecule that is extensively studied in the pathogenesis of calcium oxalate stones. Oxalobacter formigenes, a member of the colon microbiota, has important roles in oxalate homeostasis. Data regarding the colonization by and the exact role of O. formigenes in the pathogenesis of oxalic acid metabolism in HD patients are scant. Hence, we aimed to determine the relationship between fecal O. formigenes colonization, serum oxalic acid and hemodynamic parameters in HD patients with regard to the colo-reno-cardiac axis. Methods: Fifty HD patients were enrolled in this study. PWV and central aortic systolic (cASBP) and diastolic blood pressures (cADBP) were measured with a Mobil-O-Graph (I.E.M. GmbH, Stolberg, Germany). Serum oxalic acid levels were assessed by ELISA, and fecal O. formigenes DNA levels were isolated and measured by real-time PCR. Results: Isolation of fecal O. formigenes was found in only 2 HD patients. One of them had 113,609 copies/ml, the other one had 1,056 copies/ml. Serum oxalic acid levels were found to be positively correlated with PWV (r = 0.29, p = 0.03), cASBP (r = 0.33, p = 0.001) and cADBP (r = 0.42, p = 0.002) and negatively correlated with LDL (r = -0.30, p = 0.03). In multivariate linear regression analysis, PWV was independently predicted by oxalic acid, glucose and triglyceride. Conclusions: This is the first study that demonstrates the absence of O. formigenes as well as a relation between serum oxalic acid and cASBP, cADBP and PWV in HD patients. Replacement of O. formigenes with pre- and probiotics might decrease serum oxalic acid levels and improve cardiovascular outcomes in HD patients.

Keywords:
Oxalobacter formigenes, Oxalic acid, Pulse wave velocity, Central aortic blood pressures, Colo-reno-cardiac axis
1.
Collins AJ: Cardiovascular mortality in end-stage renal disease. Am J Med Sci 2003;325:163-167.
2.
de Jager DJ, Grootendorst DC, Jager KJ, van Dijk PC, Tomas LM, Ansell D, et al: Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA 2009;302:1782-1789.
3.
Evenepoel P, Meijers BK, Bammens BR, Verbeke K: Uremic toxins originating from colonic microbial metabolism. Kidney Int Suppl 2009;114:S12-S19.
4.
Meijers BK, Evenepoel P: The gut-kidney axis: indoxyl sulfate, p-cresyl sulfate and CKD progression. Nephrol Dial Transplant 2011;26:759-761.
5.
Meijers B, Toussaint ND, Meyer T, Bammens B, Verbeke K, Vanrenterghem Y, et al: Reduction in protein-bound solutes unacceptable as marker of dialysis efficacy during alternate-night nocturnal hemodialysis. Am J Nephrol 2011;34:226-232.
6.
Goldfarb DS, Modersitzki F, Asplin JR: A randomized, controlled trial of lactic acid bacteria for idiopathic hyperoxaluria. Clin J Am Soc Nephrol 2007;2:745-749.
7.
Curhan GC: Epidemiology of stone disease. Urol Clin North Am 2007;34:287-293.
8.
Kelly JP, Curhan GC, Cave DR, Anderson TE, Kaufman DW: Factors related to colonization with Oxalobacter formigenes in US adults. J Endourol 2011;25:673-679.
9.
Ferraro PM, Taylor EN, Gambaro G, Curhan GC: Soda and other beverages and the risk of kidney stones. Clin J Am Soc Nephrol 2013;8:1389-1395.
10.
Turkmen K, Erdur FM: The relationship between colonization of Oxalobacter formigenes serum oxalic acid and endothelial dysfunction in hemodialysis patients: from impaired colon to impaired endothelium. Med Hypotheses 2015;84:273-275.
11.
Chitalia N, Ismail T, Tooth L, Boa F, Hampson G, Goldsmith D, et al: Impact of vitamin D supplementation on arterial vasomotion, stiffness and endothelial biomarkers in chronic kidney disease patients. PLoS One 2014;9:e91363.
12.
Asmar R, Benetos A, Topouchian J, Laurent P, Pannier B, Brisac AM, et al: Assessment of arterial distensibility by automatic pulse wave velocity measurement. Validation and clinical application studies. Hypertension 1995;26:485-490.
13.
Hida M, Aiba Y, Sawamura S, Suzuki N, Satoh T, Koga Y: Inhibition of the accumulation of uremic toxins in the blood and their precursors in the feces after oral administration of Lebenin, a lactic acid bacteria preparation, to uremic patients undergoing hemodialysis. Nephron 1996;74:349-355.
14.
Yasuda G, Shibata K, Takizawa T, Ikeda Y, Tokita Y, Umemura S, et al: Prevalence of constipation in continuous ambulatory peritoneal dialysis patients and comparison with hemodialysis patients. Am J Kidney Dis 2002;39:1292-1299.
15.
Kalantar-Zadeh K, Kopple JD, Deepak S, Block D, Block G: Food intake characteristics of hemodialysis patients as obtained by food frequency questionnaire. J Ren Nutr 2002;12:17-31.
16.
Wu MJ, Chang CS, Cheng CH, Chen CH, Lee WC, Hsu YH, et al: Colonic transit time in long-term dialysis patients. Am J Kidney Dis 2004;44:322-327.
17.
Bammens B, Verbeke K, Vanrenterghem Y, Evenepoel P: Evidence for impaired assimilation of protein in chronic renal failure. Kidney Int 2003;64:2196-2203.
18.
Hatch M, Cornelius J, Allison M, Sidhu H, Peck A, Freel RW: Oxalobacter sp reduces urinary oxalate excretion by promoting enteric oxalate secretion. Kidney Int 2006;69:691-698.
19.
Jiang Z, Asplin JR, Evan AP, Rajendran VM, Velazquez H, Nottoli TP, et al: Calcium oxalate urolithiasis in mice lacking anion transporter Slc26a6. Nat Genet 2006;38:474-478.
20.
Hatch M, Gjymishka A, Salido EC, Allison MJ, Freel RW: Enteric oxalate elimination is induced and oxalate is normalized in a mouse model of primary hyperoxaluria following intestinal colonization with Oxalobacter. Am J Physiol Gastrointest Liver Physiol 2011;300:G461-G469.
21.
Hoppe B, Dittlich K, Fehrenbach H, Plum G, Beck BB: Reduction of plasma oxalate levels by oral application of Oxalobacter formigenes in 2 patients with infantile oxalosis. Am J Kidney Dis 2011;58:453-455.
22.
Hatch M, Freel RW, Vaziri ND: Intestinal excretion of oxalate in chronic renal failure. J Am Soc Nephrol 1994;5:1339-1343.
23.
Mogna L, Pane M, Nicola S, Raiteri E: Screening of different probiotic strains for their in vitro ability to metabolise oxalates: any prospective use in humans? J Clin Gastroenterol 2014;48(suppl 1):S91-S95.
24.
Prokopovich S, Knight J, Assimos DG, Holmes RP: Variability of Oxalobacter formigenes and oxalate in stool samples. J Urol 2007;178:2186-2190.
25.
Salminen S, Isolauri E, Salminen E: Clinical uses of probiotics for stabilizing the gut mucosal barrier: successful strains and future challenges. Antonie Van Leeuwenhoek 1996;70:347-358.
26.
Otles S, Cagindi O, Akcicek E: Probiotics and health. Asian Pac J Cancer Prev 2003;4:369-372.
27.
Nielsen B, Gurakan GC, Unlu G: Kefir: a multifaceted fermented dairy product. Probiotics Antimicrob Proteins 2014;6:123-135.
28.
Garrote GL, Abraham AG, De Antoni GL: Chemical and microbiological characterisation of kefir grains. J Dairy Res 2001;68:639-652.
29.
Marsh AJ, O'Sullivan O, Hill C, Ross RP, Cotter PD: Sequencing-based analysis of the bacterial and fungal composition of kefir grains and milks from multiple sources. PLoS One 2013;8:e69371.
30.
Zarrati M, Salehi E, Nourijelyani K, Mofid V, Zadeh MJ, Najafi F, et al: Effects of probiotic yogurt on fat distribution and gene expression of proinflammatory factors in peripheral blood mononuclear cells in overweight and obese people with or without weight-loss diet. J Am Coll Nutr 2014;33:417-425.
31.
Poesen R, Viaene L, Verbeke K, Claes K, Bammens B, Sprangers B, et al: Renal clearance and intestinal generation of p-cresyl sulfate and indoxyl sulfate in CKD. Clin J Am Soc Nephrol 2013;8:1508-1514.
32.
Poesen R, Meijers B, Evenepoel P: The colon: an overlooked site for therapeutics in dialysis patients. Semin Dial 2013;26:323-332.
33.
Protogerou AD, Papaioannou TG, Blacher J, Papamichael CM, Lekakis JP, Safar ME: Central blood pressures: do we need them in the management of cardiovascular disease? Is it a feasible therapeutic target? J Hypertens 2007;25:265-272.
34.
Weir MR, Townsend RR, Fink JC, Teal V, Anderson C, Appel L, et al: Hemodynamic correlates of proteinuria in chronic kidney disease. Clin J Am Soc Nephrol 2011;6:2403-2410.
35.
Weiss W, Gohlisch C, Harsch-Gladisch C, Tolle M, Zidek W, van der Giet M: Oscillometric estimation of central blood pressure: validation of the Mobil-O-Graph in comparison with the SphygmoCor device. Blood Press Monit 2012;17:128-131.
36.
Blacher J, Safar ME, Guerin AP, Pannier B, Marchais SJ, London GM: Aortic pulse wave velocity index and mortality in end-stage renal disease. Kidney Int 2003;63:1852-1860.
37.
Mydlik M, Derzsiova K: Oxalic acid - important uremic toxin (in Slovak). Vnitr Lek 2010;56:695-701.
38.
France NC, Holland PT, Wallace MR: Contribution of dialysis to endogenous oxalate production in patients with chronic renal failure. Clin Chem 1994;40:1544-1548.
39.
Costello JF, Sadovnic MJ, Cottington EM: Plasma oxalate levels rise in hemodialysis patients despite increased oxalate removal. J Am Soc Nephrol 1991;1:1289-1298.
40.
Phan O, Ivanovski O, Nguyen-Khoa T, Mothu N, Angulo J, Westenfeld R, et al: Sevelamer prevents uremia-enhanced atherosclerosis progression in apolipoprotein E-deficient mice. Circulation 2005;112:2875-2882.
41.
Brandenburg VM, Schlieper G, Heussen N, Holzmann S, Busch B, Evenepoel P, et al: Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study. Nephrol Dial Transplant 2010;25:2672-2679.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.